The preclinical development work is progressing for Idogen's cell therapy IDO T, which is intended to prevent organ rejection in transplantations, primarily kidney transplantations with a living donor. BioStock contacted Bo-Göran Ericzon, professor of Transplant Surgery at Karolinska Institutet, to clarify the value of innovative treatments in the field of transplantation.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/leading-transplant-surgeon-about-idogens-cell-therapy/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/idogen/r/biostock-leading-transplant-surgeon-about-idogen-s-cell-therapy,c3524187

(c) 2022 Cision. All rights reserved., source Press Releases - English